Business
Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering
CUPERTINO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that it intends to offer shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase shares of common stock in a public off
About this update from Reviva Pharmaceuticals Holdings, Inc.
[{"type":"image","alt":"Reviva Pharmaceuticals","displaySize":"","headline":null,"caption":"Reviva Pharmaceuticals","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":138,"url":"https://media.zenfs.com/en/globenewswire.com/41c0f5cc737db653c49d46fe5ad892c8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/D8sDX1mL7wV8j6M4A9rWcA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/41c0f5cc737db653c49d46fe5ad892c8","width":300,"height":138}},"lazy":false},{"type":"text","content":"CUPERTINO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that it intends to offer shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase shares of common stock in a public offering. All of the securities to be sold in the offering are to be offered by Reviva. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.","length":774,"tagName":"p"},{"type":"text","content":"A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.","length":87,"tagName":"p"},{"type":"text","content":"The Company currently intends to use the net proceeds from the offering to fund research and development activities and for working capital and other general corporate purposes.","length":177,"tagName":"p"},{"type":"text","content":"The securities will be offered pursuant to an effective shelf registration statement on Form S-3 (File No. 333-276848), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 2, 2024, and declared effective by the SEC on February 13, 2024. A preliminary prospectus supplement will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and accompanying base prospectus, when available, may be obtained from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by...